News & Updates

Show Multimedia Only
Nirmatrelvir-ritonavir benefits persist against COVID

Nirmatrelvir-ritonavir benefits persist against COVID

07 Nov 2023 byElvira Manzano

Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options. 

Nirmatrelvir-ritonavir benefits persist against COVID

07 Nov 2023
Cefazolin beneficial in infective endocarditis caused by methicillin-susceptible S aureus

Cefazolin beneficial in infective endocarditis caused by methicillin-susceptible S aureus

06 Nov 2023
Histologic inflammation of IBD a risk factor for serious infections

Histologic inflammation of IBD a risk factor for serious infections

03 Nov 2023

Among individuals with inflammatory bowel disease (IBD), histologic inflammation appears to contribute to an increased risk of serious infections such as sepsis, according to a study, suggesting that achieving remission may reduce infections in IBD.

Histologic inflammation of IBD a risk factor for serious infections

03 Nov 2023
Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023